Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Accumulated Expenses: 2016-2025

Historic Accumulated Expenses for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $15.0 million.

  • Tg Therapeutics' Accumulated Expenses rose 48.87% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 48.87%. This contributed to the annual value of $15.2 million for FY2024, which is 24.75% up from last year.
  • As of Q3 2025, Tg Therapeutics' Accumulated Expenses stood at $15.0 million, which was up 41.51% from $10.6 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Accumulated Expenses peaked at $15.2 million during Q4 2024, and registered a low of $1.6 million during Q1 2022.
  • Its 3-year average for Accumulated Expenses is $8.8 million, with a median of $8.3 million in 2023.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 158.55% in 2021, then plummeted by 66.57% in 2022.
  • Quarterly analysis of 5 years shows Tg Therapeutics' Accumulated Expenses stood at $10.2 million in 2021, then decreased by 17.06% to $8.4 million in 2022, then skyrocketed by 44.35% to $12.2 million in 2023, then rose by 24.75% to $15.2 million in 2024, then spiked by 48.87% to $15.0 million in 2025.
  • Its last three reported values are $15.0 million in Q3 2025, $10.6 million for Q2 2025, and $5.1 million during Q1 2025.